This novel mechanism of action suggests that, in addition to B-cell lymphomas, Btk inhibitors may also displayed impressive therapeutic potency in lymphatic malignancies and solid tumors lacking Btk expression. This evidence concerns the gene BTK and B-cell non-Hodgkin lymphoma.